SALT LAKE CITY, UT – Recursion Pharmaceuticals, a biotechnology company that combines innovative biological science with artificial intelligence to discover new disease treatments at scale, today announced the formation of a research collaboration agreement with Takeda Pharmaceutical Company Limited (TSE: 4502). Under the terms of this collaboration, Recursion will utilize its discovery platform to provide pre-clinical candidates for Takeda’s TAK-celerator™ development pipeline in the next year. The collaboration is designed to leverage the most advanced high-throughput biology and artificial intelligence techniques to get potential treatments for rare diseases into the clinic more quickly, safely, and at lower costs than ever before.
Recursion augments traditional drug discovery approaches, most prominently phenotypic screening, with artificial intelligence. By modeling thousands of diseases in human cells, and capturing hundreds of millions of microscopic images, the company is building the world’s largest biological image dataset, currently growing by more than two million new images and 20 TB of data each week. This highly relatable and comprehensively annotated dataset enables the company to train neural networks and to use other sophisticated computational techniques to identify changes in thousands of cellular and subcellular features in the presence of various biological perturbations. This approach, which the company dubs ‘Phenomics’, enables unbiased discovery of novel biology, drug targets, or drug candidates at an unprecedented scale and pace.